Elizabeth Fox, MD

Elizabeth Fox, MD, is an attending physician and head of Developmental Therapeutics at CHOP’s Cancer Center. She has specific expertise in neuro-endocrine tumors.

Areas of Expertise: Neuro-endocrine tumors
Locations: Main Campus
Appointments and Referrals: 1-800-TRY-CHOP (1-800-879-2467)

  • Education and Training

    Medical School

    Pennsylvania State University College of Medicine

    Internship

    Strong Memorial Hospital, University of Rochester, Rochester, NY

    Residency

    Strong Memorial Hospital, University of Rochester, Rochester, NY

    Fellowship

    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD

    Board Certification

    PediatricsHematology/OncologyMedical Technology

    Graduate Degree

    Duke University College of Medicine

  • Titles and Academic Titles

    Head, Developmental Therapeutics, Division of Oncology; Attending Physician, Division of Oncology; Associate Professor of Pediatrics, Perelman School of Medicine at the University of Pennsylvania

  • Centers and Programs
  • Publications

    Books

    Chapters

    Fox E, Balis FM. Drug therapy in newborns and children. In: Atkinson AJ, Daniels CE, Dedrick RL, Grudzinskas CV, Markey SP, editors. Principles of clinical pharmacology. 2nd ed. Burlington: Academic Press; 2006.

    Fox E, Adamson PC. Future trends in cancer chemotherapy. In: Voute PA, Barrett A, Stevens, MCG, editors. Cancer in children clinical management. 5th ed. New York: Oxford University Press; 2005.

    Fox E, Adamson PC. Phase I trial design considerations in the pediatric population. In: Budman DR, Calvert AH, Rowinsky EK, editors. Handbook of anticancer drug development. Philadelphia: Lippincott Williams & Wilkins; 2003.

    Fox E, Balis FM. Drug therapy in newborns and children. In: Atkinson AJ, Daniels CE, Dedrick RL, Grudzinskas CV, Markey SP, editors. Principles of clinical pharmacology. Burlington: Academic Press; 2003.

    Fox E, Balis FM. Drug therapy in newborns and children. In: Atkinson AJ, Daniels CE, Dedrick RL, Grudzinskas CV, Markey SP, editors. Principles of clinical pharmacology. Burlington: Academic Press; 2001.

    Abstracts

    2010

    Pastakia D, McCully C, Bacher J, Cole D, Druz R, Blakley J, et al. Comparison of intravenous microdialysis sampling to standard blood sampling to determine free etoposide exposure (AUC) in a non-human primate model [abstract]. Proc Am Assoc Cancer Res. 2010.

    Kim A, McCully C, Cruz R, Cole D, Fox E, Balis F, et al. The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates [abstract]. Proc Am Assoc Cancer Res. 2010.

    Marcus L, Murphy R, Fox E, McCully C, Cruz R, Warren K, et al. The plasma and cerebrospinal fluid pharmacokinetics of satraplatin after intravenous administration in non-human primates [abstract]. Proc Am Assoc Cancer Res; 2010.

    Papers

    2011

    Widemann BC, Arceci RJ, Jayaprakash N, Fox E, Zannikos P, Goodspeed W, et al. Phase I trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2011 Feb;56(2):226-33. doi: 10.1002/pbc.22775. Epub 2010 Sep 21. Cited in PubMed: PMID 20860038. Read the abstract

    Chuk MK, Cole D, McCuly CL, Loktionova N, Pegg A, Pauly G, et al. Plasma and CND pharmacokinetics of O4-benzylfolic acid (O4BF) and metabolite in a non-human primate model. Cancer Chemother Pharmacol. 2011 Jun;67(6):1291-7. Epub 2010 Aug 20. Cited in PubMed: PMID 20725726. Read the abstract

    2010

    Lipsitz E, Moorthy G, Mosse Y, Fox E, Adamson PC. A sensitive and selective liquid chromatography/tandem mass spectrometry method for determination of MLN8237 in human plasma. J Chromatogr B. 2010 Sep 1;878(25):2369-73. Epub 2010 Jul 3. Cited in PubMed: PMID 20685183. Read the abstract

    Fox E, Aplenc R, Chuk M, Widemann BC, Bagatell R, Goodspeed W, et al. Phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor in children and adolescents with refractory solid tumors. J Clin Oncol. 201 Dec 10;28(35):5174-81. Epub 2010 Nov 8. Cited in PubMed: PMID 21060028. Read the abstract

    Fox E, Jayaprakash N, Pham T-H, Rowley A, McCully C, Pucino F, Goldbach-Mansky R. The serum and cerebrospinal fluid pharmacokinetics of anakinra after intravenous administration to non-human primates. J Neuroimmunol. 2010 Jun;223(1-2):138-40. Epub 2010 Apr 24. Cited in PubMed: PMID 20421138. Read the article

    Widemann BC, Balis FM, Kim A, Boron M, Jayaprakash N, Shalabi A, et al. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate induced renal dysfunction: clinical and pharmacologic factors impacting outcome. J Clin Oncol. 2010 Sep 1, 28(25):3979-86. Epub 2010 Aug 2. Cited in PubMed: PMID 20679598. Read the abstract

    Paoloni M, Mazcko C, Fox E, Fan T, Lana S, Kisseberth W, et al. Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: a comparative oncology study in dogs. PLoS One 5(6):e11013. Cited in PubMed: PMID 20543980. Read the article

    Meany H, Balis FM, Aikin A, Whitcomb P, Murphy R, Steinberg S, et al. Pediatric phase I trial design using maximum target inhibition as the primary endpoint. J Natl Cancer Inst. 2010 Jun 16;102(12):909-12. Epub 2010 May 11. Cited in PubMed: PMID  2046032. Read the article

    Fox E, Maris JM, Cohn JM, Goodspeed W, Goodwin A, Kromplewski M, et al. Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors. Cancer Chemother Pharmacol. 2010 Sep;66(4):737-43. Epub 2010 Jan 1. Cited in PubMed: PMID 20044751. Read the abstract

    Jacobs S, Fox E, Krailo MD, Hartley G, Navid F, Wexler L, et al. Phase II trial of ixabepilone (BMS-247550) in children and young adults with refractory solid tumors: a report from the Children's Oncology Group. Clin Cancer Res. 2010 Jan 15;16(2):750-4. Epub 2010 Jan 12. Cited in PubMed: PMID 20068084. Read the article

    Meany HJ, Sackett DI, Maris JM, Ward Y, Krivoshik A, Cohn SL, et al. Clinical outcome in children with recurrent neuroblastoma treated with ABT-751 and effect of ABT-751 on proliferation of neuroblastoma cell lines and tubulin polymerization in vitro. Pediatr Blood Cancer. 2010 Jan;54(1):47-54. Cited in PubMed: PMID 19731320. Read the article

  • Editorial and Academic Positions

    Editorial positions

    Editorial boards

    2007-present, Associate Editor, Journal of the National Cancer Institute

    Scientific reviewer

    Blood
    Cancer Chemotherapy & Pharmacology
    Cancer Research
    Clinical Cancer Research
    Journal of Clinical Oncology
    Journal of the National Cancer Institute
    Journal of Pediatric Hematology & Oncology
    Journal of Pharmacology & Experimental Therapeutics
    Pediatric Blood & Cancer

    Academic positions

    2008-present, NCI Seminar Series Organizational Committee, Pediatric Oncology Branch

    2008-present, Children's Oncology Group Neuroblastoma Committee, Task Force for Study Design of Maintenance Therapy for High Risk Neuroblastoma

    2008-present, Biomedical Research Information System Development Task Force Center for Cancer Research, NCI

    2007-present, Pediatric Oncology Branch, NCI Web Development Committee

    2006-present, Children's Oncology Group Neuroblastoma Committee

    2006-present, Children's Oncology Group Trial Design and Endpoints in Neuroblastoma Task Force

    2004-present, Center for Cancer Research Early Drug Development Committee

    Children's Oncology Group Study Committees

    • ADVL1021 Phase 2 Study of Cediranib in Children With Refractory Solid Tumors
    • ADVL0811 Phase I Study of AZ2281, Oral PARP Inhibitor in Combination With Temozolomide or Irinotecan
    • ADVL0721 Phase 2 Trial of ABT-751 in Children With Ewings Sarcoma, Osteosarcoma, Rhabdomyosarcoma, or Wilms Tumor
    • ANBL0621 Phase 2 Trial of ABT-751 in Children With Refractory Neuroblastoma
    • ADVL0524 Phase 2 Trial of Ixabepilone in Children With Refractory Solid Tumors
    • ADVL0413 Phase I Study of Sorafenib in Children With Relapsed Solid Tumors